ASH: Despite Novel Drugs In CML, Older Agents Are Tough To Dislodge
Superiority Data Vs. Generic Options
Scemblix proved more efficacious than older TKIs, but the older drugs may maintain a presence for economic reasons, though Takeda’s Iclusig may see a diminished role due to tolerability concerns.
